Jci_page_head_homepage_01 Jci_page_head_homepage_02
Reiko Horai, Akiko Nakajima, Katsuyoshi Habiro, Motoko Kotani, Susumu Nakae, Taizo Matsuki, Aya Nambu, Shinobu Saijo, Hayato Kotaki, Katsuko Sudo, Akihiko Okahara, Hidetoshi Tanioka, Toshimi Ikuse, Naoto Ishii, Pamela L. Schwartzberg, Ryo Abe, Yoichiro Iwakura
Published in Volume 114, Issue 11
J Clin Invest. 2004; 114(11):1603–1611 doi:10.1172/JCI20742
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6

Anti-CD40L or anti-OX40L Ab treatment of IL-1Ra–/– mice. Blocking Abs against either CD40L or OX40L were administrated to IL-1Ra–/– mice before the onset of arthritis. Ab treatment was continued twice a week for 6 weeks, and incidence of arthritis was inspected each time before Ab administration. Incidence and severity score of arthritis in control hamster IgG_treated (open squares, n = 8) or anti-CD40L Ab_treated (filled squares, n = 8) IL-1Ra–/– mice (A and B) and those in control rat IgG_treated (open diamonds, n = 8) or anti-OX40L Ab_treated (closed diamonds, n = 8) IL-1Ra–/– mice (C and D). *P < 0.01 by repeated-measures ANOVA or 2-way ANOVA.